Vericel Corporation (VCEL) Stock Score, Valuation & Financial Research
Vericel Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 39/100.
Quick answer for VCEL
Vericel Corporation currently has a Wall Street Score of 39/100. The stored market price is $38.34. Its financial score is 34/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Vericel Corporation does
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc.,
VCEL financial snapshot
- Wall Street Score:
- 39/100
- Current price:
- $38.34
- Market capitalization:
- $1.96B
- Revenue:
- $292.1M
- Net income:
- $21.5M
- Free cash flow:
- $24.7M
- Cash:
- $109.3M
- Total debt:
- $94.5M
- EPS:
- 0.33
- P/E ratio:
- 116.2x
- Financial score:
- 34/100
- Valuation score:
- 0/100
- Revenue score:
- 26/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $24.7M, showing positive cash generation.
- The balance sheet shows $109.3M of cash versus $94.5M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 34/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research VCEL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.